Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis.
Lancet Neurol. 2010;9(6):599-612.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
N Engl J Med. 2010;362(5):402-415.
FDA approves Ampyra to improve walking in adults with multiple sclerosis. US Food and Drug Administration website. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm. Updated April 25, 2013. Accessed August 28, 2015.
FDA approves first oral drug to reduce MS relapses. US Food and Drug Administration website. Available at:
Updated April 19, 2013. Accessed August 28, 2015.
International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study.
N Engl J Med.
Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study.
J Infect Dis.
Kasper DL, Braunwald E, et al.
Harrison’s Principles of Internal Medicine. 16th ed. The McGraw-Hill Companies; 2006.
Kappos L, Radue EW. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
N Eng J Med. 2010;362(5):387-401.
Multiple sclerosis. EBSCO DynaMed Plus website. Available at:
http://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS. Updated March 4, 2016. Accessed September 26, 2016.
NINDS multiple sclerosis information page.
National Institute of Neurological Disorders and Stroke
website. Available at:
Updated July 17, 2015. Accessed August 28, 2015.
Rose JW, Carlson NG. Pathogenesis of multiple sclerosis.
Continuum Lifelong Learning Neurol.
Treating MS. National Multiple Sclerosis Society. Available at
http://www.nationalmssociety.org/Treating-MS. Accessed August 28, 2015.
What is MS?
National Multiple Sclerosis Society website. Available at:
http://www.nationalmssociety.org/What-is-MS. Accessed August 28, 2015.
Van der Mae IA, Simpson S Jr, Stankovich J, Taylor BV. Individual and joint action of environmental risk factors and MS.
Neurol Clin. 2011;29(2):233-55.
1/4/2011 DynaMed Plus Systematic Literature Surveillance
http://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS: Healy B, Ali E, Guttmann C, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009;66(7):858-864.
4/25/2014 DynaMed Plus Systematic Literature Surveillance http://www.dynamed.com/topics/dmp~AN~T905969/Treatment-of-specific-impairments-in-multiple-sclerosis: Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014;2:CD009131.
4/25/2014 DynaMed Plus Systematic Literature Surveillance http://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS: Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-1092.
11/9/2015 DynaMed Plus Systematic Literature Surveillance http://www.dynamed.com/topics/dmp~AN~T116285/Multiple-sclerosis-MS: Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015;175(9):1518-1526.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.